Cancer cytopathology · 2025
FNA biopsy of breast specimens effectively harvests cells for patient-derived organoids modeling ductal carcinoma in situ.
СтатьяПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ye Julia, Goldhammer Nadine, Vohra Poonam, Warhadpande Shruti, de Castro George C, Rodas Cristian K Maldonado, Moasser Mark M, Ramalingam Kirithiga, Abe Shoko E, Alvarado Michael, Ewing Cheryl, Goodwin Karen M, Mukhtar Rita A, Wong Jasmine M, Esserman Laura J, Balassanian Ronald, Rosenbluth Jennifer M
Аннотация
BACKGROUND: Patient-derived organoids (PDOs) generated from benign breast tissue and breast carcinomas have successfully recapitulated their in vivo counterparts. PDOs model tumorigenesis and allow for screening novel therapeutics personalized to individual patients. However, acquiring cells to generate PDOs is cumbersome. This study demonstrates the feasibility of fine-needle aspiration biopsy (FNAB) for harvesting cells for PDOs modeling ductal carcinoma in situ (DCIS) and compares the efficacy with core needle biopsy (CNB).
METHODS: Surgical specimens from patients with biopsy-proven DCIS were used for this study. CNB was performed on fresh specimens in the operating room, and tissue was mechanically dissociated before culture in basement membrane extract (BME) and organoid medium to generate PDOs. FNAB was performed in the pathology gross room on fresh specimens, and the aspirate was similarly submitted for culture.
RESULTS: PDOs were successfully generated in 15 of 18 specimens obtained by CNB and seven of 11 specimens obtained by FNAB. The average time to initial organoid growth was 4 days for FNAB specimens compared to 19.3 days for CNB specimens. Tumor cells were seen on seven of 11 FNAB smears and 16 of 18 CNB touch preps. Immunofluorescence staining confirmed the presence of both luminal and myoepithelial cells in derived PDOs.
CONCLUSIONS: FNAB effectively obtains cells for PDOs modeling DCIS. CNB yielded PDOs with a high success rate, but they were slow to establish. The time to organoid growth was significantly shorter for FNAB specimens. Thus, FNAB offers an efficient alternative for breast PDO culture and can reduce the time and resources spent on generating PDO cultures.
METHODS: Surgical specimens from patients with biopsy-proven DCIS were used for this study. CNB was performed on fresh specimens in the operating room, and tissue was mechanically dissociated before culture in basement membrane extract (BME) and organoid medium to generate PDOs. FNAB was performed in the pathology gross room on fresh specimens, and the aspirate was similarly submitted for culture.
RESULTS: PDOs were successfully generated in 15 of 18 specimens obtained by CNB and seven of 11 specimens obtained by FNAB. The average time to initial organoid growth was 4 days for FNAB specimens compared to 19.3 days for CNB specimens. Tumor cells were seen on seven of 11 FNAB smears and 16 of 18 CNB touch preps. Immunofluorescence staining confirmed the presence of both luminal and myoepithelial cells in derived PDOs.
CONCLUSIONS: FNAB effectively obtains cells for PDOs modeling DCIS. CNB yielded PDOs with a high success rate, but they were slow to establish. The time to organoid growth was significantly shorter for FNAB specimens. Thus, FNAB offers an efficient alternative for breast PDO culture and can reduce the time and resources spent on generating PDO cultures.